# ANLONG

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/anlong

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.anlongbio.com
- Total disclosed funding: $20M
- Latest round: Series B (Jan 7, 2026)
- Investors on record: 11

## About

Based in Beijing, China and founded in 2019, Beijing Anlong Biomedical Co., Ltd., trading as ANLONG, operas as a gene therapy company which focuses on ophthalmology. The company has a 5000 square meter R&D and GMP production base in zhongguancun medical transformation center. The founder and CEO, Zhao Chunlin, has more than 30 years entrepreneurship and investment experience in the field of scientific research, multinational pharmaceutical companies, domestic pharmaceuticals and medical instrument. In January 2026, ANLONG raised approximately CNY 100 million in Series B+ funding from new investors Shunyi Industry Capital and Shunxi Fund.

ANLONG focuses on nucleic acid drugs, include gene therapy, gene editing, RNA drugs, oncolytic viruses and other new drug development technology. Besides, the company focuses on gene therapy of wet macular degeneration wAMD and AAV vector screening. The company mainly focuses on the field of ophthalmology, blood, neuromuscular system and cardio-cerebrovascular system.

The company generates revenue by developing new drugs using technologies such as gene regulation, gene therapy, and gene editing.

The funding raised in January 2026 will be used to advance the research and clinical translation of its gene therapy project for wet age-related macular degeneration (wAMD) and its AAV vector screening technology.

## Funding rounds

- Series B, Jan 7, 2026, $14M — Shunxi Fund, Shunyi Industry Capital
- Series A, Jan 23, 2024 — Taikun Fund, Shunchuang Industrial Investment
- Series A, Jun 9, 2021 — HighLight Capital, Oceanpine Capital, Tigermed, TigerYeah Capital, CITIC Med Fund, Origins Capital
- Series A, Jul 8, 2020, $5.7M — Yingke Private Equity

## Investors

- Yingke Private Equity (https://capitalatlas.ai/funds/yingke-private-equity) — Series A
- HighLight Capital (https://capitalatlas.ai/funds/highlight-capital) — Series A
- Oceanpine Capital (https://capitalatlas.ai/funds/oceanpine-capital) — Series A
- Tigermed (https://capitalatlas.ai/funds/tigermed) — Series A
- TigerYeah Capital (https://capitalatlas.ai/funds/tigeryeah-capital) — Series A
- CITIC Med Fund (https://capitalatlas.ai/funds/citic-med-fund) — Series A
- Origins Capital (https://capitalatlas.ai/funds/origins-capital) — Series A
- Taikun Fund — Series A
- Shunchuang Industrial Investment (https://capitalatlas.ai/funds/shunchuang-industrial-investment) — Series A
- Shunxi Fund (https://capitalatlas.ai/funds/shunxi-fund) — Series B
- Shunyi Industry Capital (https://capitalatlas.ai/funds/shunyi-industry-capital) — Series B